Compare CVS Health Corp (CVS) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Ferrari NV — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Ferrari NV trades at $391.01 (market cap $67.35B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Ferrari NV for 126 Days on average.
| CVS | RACE | |
|---|---|---|
Market Cap | $112.49B | $67.35B |
Volume | 8,467,392 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $436.54 |
52-Week Low | $70.08 | $314.63 |
Typical Hold Time | 83 Days | 126 Days |
Enterprise Value | $174.83B | $69.22B |
Dividend Yield | 3.02% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Ferrari (RACE) trades at $386.39, down slightly by 0.03% today. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $2.49 vs. $2.44 expected, Q1 2026: $2.73 vs. $2.70 expected, Q2 2026: $2.99 vs. $2.83 expected) and robust profitability (net margin 22.25%, ROE 45.45%). Technical indicators are bearish overall, with the current price near support at $385. Recent news highlights a share buyback program and partnership with Rakuten effective January 2027.
Outlook: Analyst consensus is bullish with a $462.75 price target (73.69% buy ratings). Opportunities include strong brand equity, margin expansion, and strategic initiatives. Risks involve high valuation multiples (P/E 37.19, P/S 8.25), economic sensitivity, and execution of growth plans. The stock offers growth potential but requires monitoring of valuation and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
